INTRODUCTION
Phenothiazines and other older antipsychotics drugs are being replaced by atypical antipsychotics. Atypical antipsychotics have a low risk of adverse extra pyramidal effect. The effectiveness against negative and positive symptoms of schizophrenia is attributed to their high affinity to 5HT2A and D4 receptor and also antagonistic action against alpha adrenergic, muscarnic& H 1 and D 2 receptor 1 . Weight gain is common with Phenothiazines, Haloperidal, Thioxanthenes and Atypical antipsychotics like olanzapine, Clozapine. Weight gain is less common with Risperidone, Quetiapine Ziprasidone which are also atypical antipsychotics. Psychiatric patients need long term treatment with antipsychotics. Weight gain produced by antipsychotics may increase the risk of new onset Type2Diabetes mellitus 2 . Weight gain and development or exacerbation of Diabetes mellitus are serious issues that have forced clinicians to vigilantly follow up their patient's metabolic profile to prevent serious consequences 3 .Studies have shown that use of risperidone in non diabetic schizhophrenic patients cause increase in the levels of fasting blood sugar levels from the baseline values .Hence this study stresses the monitoring of the fasting blood sugar during the treatment with risperidone. Many drugs cause diabetes mellitus and these are antipsychotics risperidone, olanzepine, clozapine in particular, and also other drugs like thiazide, B blockers, corticosteroids phenytoin sodium, tacrolimus , estrogen ,progesterone preparation and certain antidepressents. 4 US regulators have proposed that 6 antipsychotics medication can increase the risk of impaired glucose tolerance and diabetes. These drugs are risperidone ,olanzepine , clozapine, quetiapine,ziprazidone,aripiprazole 5 .Hence it was decided to conduct a study using risperidone in non diabetic psychiatric patients to find out if risperidone really causes changes in glucose tolerance, and has been designed accordingly.
In this study already known diabetics and those diagnosed to have diabetes mellitus at the time of study were not included because this study is to find out the effect of risperidone on blood sugar level who are having normal blood sugar level . If it is found out Risperidone produces Carbohydrate intolerence ,then the study could also be conducted on diabetics. The blood sugar levels were monitored at beginning of the study, 4 weeks and at 8 weeks and reports were analyzed. Results were presented asmean ± standard error. Results were analyzed using paired sample t test. Differences were considered significant when P value of <0.05. Mean age of the participants were 52. Among this sixty two percent were male and thirty eight percent were female. Twenty males and ten females completed the study. The mean FBS level was increased from87.56 mg/dl (baseline) to 94.56mg/dl at 4week and 101.76mg/dl at 8weeks.The FBS levels at 8 weeks were significantly different from baseline FBS levels (p<0.001)
Sex distribution:

Mean fasting blood sugar level:
Mean postprandial blood sugar: The mean PPBS was increased from111.68 mg/dl (baseline) to127.12mg/dl at 4week and 147.88 mg/dl at 8week.The PPBS level at 8week were significantly different from baseline PPBS level (p<0.001) The patient's Bodyweight was increased from59.16 (baseline) to59.49 at4 weeks and59.96 at 8weeks.The weight gain was statistically significant ( p=0.001)
Mean body weight:
DISCUSSION:
In this study the effect of risperidone on blood glucose level in non diabetic patients of psychiatric illness showed there was significant increase in both fasting and post prandial blood glucose level at the end of 4weeks and at the end of 8 weeks. Though there is increase in both FBS and PPBS level in patients treated with risperidone, at the end of 4week and at the end of 8week,the increases are well within normal limits. There was also statistically significant increase in body weight as shown in the table.
The mechanism by which risperidone causes increase in blood sugar level was not fully understood. However the proposed mechanisms are; weight gain, insulin resistence increase in leptins concentration and glucose transport impairment 6 .
Therefore regular monitoring of blood glucose before starting risperidone to prevent further complication is necessary.
The studies show that there is definite increase in FBS, PPBS in patients who have given risperidone .As noted already all the patients were non diabetics.
The effect of risperidone in blood sugar level in patients who are preexisting diabetics has not been studied till now. In such cases risperidone and other antipsychotics as mentioned in the initial part of the study, may aggravate preexisting diabetics, when risperidone is given to treat the psychiatric illness.
This may interferes with control of blood glucose level and it may be necessary to increase the dosage of anti diabetic drugs. In this study it has been shown risperidone definitely impairs glucose tolerance. Only further studies can establish the role of risperidone in interfering glucose tolerance.
From this study it has also transpired that blood sugar levels should be estimated in all the patients receiving risperidone, if not, in all the patients at least in those who are potentially diabetics .Since atypical antipsychotics 
BW_BL BW_4w BW_8w
Mean Mean
